
Opinion|Videos|June 21, 2024
Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following questions:
- For patients who no longer benefit from prior endocrine therapy, what is your current approach to treatment sequencing in HR+/HER2-low metastatic breast cancer?
- What are some unmet needs and ongoing challenges in patients with HR+/HER2-low breast cancer?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















